Compare Stocks

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRMA Dermata Therapeutics	$0.34 +6.3%	$0.41	$0.23 ▼ $3.68	$2.26M	0.87	719,320 shs	37,777 shs
RUBY Rubius Therapeutics	$0.06	$0.04	$0.00 ▼ $0.38	$5.16M	2.59	1.15 million shs	755,858 shs
SINT Sintx Technologies	$0.04	$0.09	$0.02 ▼ $1.82	$862K	1.47	21.72 million shs	44.20 million shs
SNES SenesTech	$0.74 +4.2%	$0.82	$0.52 ▼ $19.20	$3.82M	0.85	453,091 shs	29,418 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRMA Dermata Therapeutics	+5.45%	+12.79%	-18.45%	-19.38%	-87.13%
RUBY Rubius Therapeutics	0.00%	0.00%	0.00%	0.00%	+143.59%
SINT Sintx Technologies	-9.09%	+73.52%	-58.92%	-87.84%	-97.90%
SNES SenesTech	+3.54%	-6.97%	+8.04%	-19.22%	-95.67%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SINT Sintx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNES SenesTech	2.2262 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.0	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A
SINT Sintx Technologies	2.00	Hold	N/A	N/A
SNES SenesTech	3.00	Buy	$3.50	370.87% Upside

Current Analyst Ratings

Latest SNES, SINT, DRMA, and RUBY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/5/2024	SINT Sintx Technologies	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	$0.17 per share	N/A
SINT Sintx Technologies	$2.63M	0.33	N/A	N/A	$1.65 per share	0.02
SNES SenesTech	$1.19M	3.21	N/A	N/A	$1.24 per share	0.60

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRMA Dermata Therapeutics	-$7.80M	-$3.65	N/A	∞	N/A	N/A	-107.95%	-93.59%	5/9/2024 (Estimated)
RUBY Rubius Therapeutics	-$179.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SINT Sintx Technologies	-$8.26M	-$3.42	N/A	∞	N/A	-314.39%	-67.12%	-45.49%	5/20/2024 (Estimated)
SNES SenesTech	-$7.71M	N/A	0.00	N/A	N/A	-646.27%	-199.86%	-156.79%	5/9/2024 (Estimated)

Latest SNES, SINT, DRMA, and RUBY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	SINT Sintx Technologies	N/A	-$0.09	-$0.09	-$0.09	N/A	$0.90 million
3/21/2024	Q4 2023	DRMA Dermata Therapeutics	N/A	-$0.21	-$0.21	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A
SINT Sintx Technologies	N/A	N/A	N/A	N/A	N/A
SNES SenesTech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRMA Dermata Therapeutics	N/A	4.91	4.91
RUBY Rubius Therapeutics	N/A	N/A	N/A
SINT Sintx Technologies	N/A	1.90	1.60
SNES SenesTech	0.02	8.49	7.48

Ownership

Institutional Ownership

Company	Institutional Ownership
DRMA Dermata Therapeutics	8.67%
RUBY Rubius Therapeutics	N/A
SINT Sintx Technologies	18.38%
SNES SenesTech	5.19%

Insider Ownership

Company	Insider Ownership
DRMA Dermata Therapeutics	9.40%
RUBY Rubius Therapeutics	5.30%
SINT Sintx Technologies	0.79%
SNES SenesTech	5.32%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
DRMA Dermata Therapeutics	8	6.66 million	6.38 million	Not Optionable
RUBY Rubius Therapeutics	6	90.48 million	85.69 million	Not Optionable
SINT Sintx Technologies	41	22.68 million	22.50 million	Not Optionable
SNES SenesTech	25	5.14 million	4.87 million	Not Optionable

SNES, SINT, DRMA, and RUBY Headlines

Source	Headline
	SenesTech to Present at the Emerging Growth Conference on April 3, 2024 prnewswire.com - April 2 at 9:00 AM
	SenesTech (NASDAQ: SNES) Inks Deal with Wilco Distributing for Pest-Management Products theglobeandmail.com - March 28 at 12:30 AM
	SenesTech Signs Wilco Distributing for Evolve™ and ContraPest® Distribution in Agriculture and Professional Rodent Pest Management Market finance.yahoo.com - March 27 at 2:46 AM
	SenesTech (NASDAQ: SNES) Closes Multiple Global Distribution Deals theglobeandmail.com - March 20 at 5:15 PM
	SenesTech (NASDAQ: SNES) Expanding Global Reach with Innovative Products theglobeandmail.com - March 19 at 4:48 AM
	SenesTech (NASDAQ: SNES) Announces Participation at Emerging Growth Conference theglobeandmail.com - March 7 at 2:29 AM
	SenesTech (NASDAQ: SNES) Posts Fiscal Year 2023 Results, Reports Revenue Growth theglobeandmail.com - March 6 at 4:27 PM
	SenesTech to Present at the Emerging Growth Conference on March 6, 2024 prnewswire.com - March 5 at 9:00 AM
	SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Call Transcript finance.yahoo.com - February 24 at 12:35 PM
	Earnings call: SenesTech reports solid growth and optimistic outlook investing.com - February 24 at 7:30 AM
	SenesTech (NASDAQ: SNES) Continues to Increase Rat Birth Control Product Distribution theglobeandmail.com - February 24 at 2:17 AM
	SenesTech Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - February 23 at 10:03 AM
	SenesTech (NASDAQ: SNES) Promotes Non-Lethal Rodent Birth Control Products at Lytham Investor Forum theglobeandmail.com - February 22 at 11:28 PM
	Analysts Offer Insights on Materials Companies: SenesTech (SNES) and Victoria Gold (OtherVITFF) markets.businessinsider.com - February 22 at 6:27 PM
	SenesTech, Inc.: SenesTech Announces 2023 Financial Results finanznachrichten.de - February 22 at 1:27 PM
	SenesTech reports FY results msn.com - February 22 at 1:27 PM
	SenesTech Announces 2023 Financial Results finance.yahoo.com - February 21 at 8:33 PM
	SenesTech Announces 2023 Financial Results prnewswire.com - February 21 at 4:05 PM
	Earnings Preview For SenesTech benzinga.com - February 20 at 6:58 PM
	SenesTech (SNES) Expands in the Netherlands With Q-chem Deal zacks.com - February 20 at 11:21 AM
	SenesTech, Inc.: SenesTech Announces Exclusive Distribution Agreement for Evolve Soft Bait in The Netherlands finanznachrichten.de - February 16 at 9:12 PM
	SenesTech to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Wednesday, February 21, 2024 finance.yahoo.com - February 15 at 7:00 PM
	SenesTech to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Wednesday, February 21, 2024 prnewswire.com - February 15 at 4:15 PM
	SenesTech Announces Exclusive Distribution Agreement for Evolve(TM) Soft Bait in The Netherlands stockhouse.com - February 15 at 2:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Dermata Therapeutics

NASDAQ:DRMA

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Rubius Therapeutics

NASDAQ:RUBY

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Sintx Technologies

NASDAQ:SINT

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

SenesTech

NASDAQ:SNES

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial